請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/77885
標題: | 發展功能性的二氧化矽奈米粒子應用於酵素治療 Developing Functional Silica Nanoparticles for Enzyme Therapy |
作者: | Jou-Hsuan Liao 廖柔瑄 |
指導教授: | 牟中原(Chung-Yuan Mou) |
關鍵字: | 中孔洞二氧化矽奈米粒子,空心球,蛋白治療,抗氧化酵素,化療藥物,門冬醯胺?,急性淋巴性白血病, mesoporous silica nanoparticles,hollow silica nanospheres,protein therapy,antioxidant enzymes,chemotherapy drugs,L-Asparaginase,acute lymphoblastic leukemia (ALL), |
出版年 : | 2017 |
學位: | 碩士 |
摘要: | 蛋白質治療已經成為現今治療蛋白質缺陷和折疊錯誤疾病的潛在方法。為了克服蛋白質在體內輸送的問題,如穩定性或細胞膜滲透性不佳、易被核內體困住或消化以及免疫系統自身反應等等,我們開發了二氧化矽中孔洞的奈米粒子(MSN) 和二氧化矽空心球 (HSN) 作為治療性載體應用於酵素治療。
在本研究的第一部分,我們期望設計一種二氧化矽中孔洞奈米粒子 (MSN),具有生物相容性、能夠在體內保持穩定,且施打後不會累積在器官內等特性。因此,我們在MSN的表面上修飾了長鏈的親水官能基PEG和PEI來增加細胞攝取,接著將具有抗氧化壓力的TAT-SOD蛋白接到MSN上,形成RMSN-Ni-TAT-SOD。我們比較於細胞施加RMSN-Ni-TAT-SOD的自然型態蛋白或變性蛋白之間的差異,並且專注在機制上的研究。我們根據結果提出一假說: 當TAT-SOD以變性蛋白形式接於MSN,會比自然態蛋白形式有較少的立體位障,因此能夠更有效的進行蛋白質輸送且增強SOD的活性。 在第二部分的研究,在治療急性淋巴性的白血病 (ALL) 上,我們利用引入矽烷 (silane) 將天門醯胺酶 (ASNase) 包裹於具PEG修飾的空心球內,我們發現HSN的球殼能幫助位於球內的ASNase對抗胰蛋白酶(trypsin) 的消化並穩定酵素的活性,和臨床上所使用的ASNase相比,可以有效延長在體內的半生期。除此之外,此方法的優點保留了良好的酵素活性,可有效的誘導細胞凋亡,是在ALL主要治療機制上的關鍵。據我們所知,這是第一個將ASNase包覆在HSN內,保持其良好酵素活性並用於來ALL治療的研究。 總而言之,利用二氧化矽奈米粒子來輸送蛋白質是具有展望性,我們試圖解決目前在發展及治療上遇到的困難,期望這項研究能將奈米蛋白質治療推向臨床前研究。 Protein therapy had become a potential approach in treating protein deficiency and misfolding diseases. To overcome the concerns of protein delivery including poor stability, membrane impermeability, endosome trapping/digestion and immune response, we developed mesoporous silica nanoparticles (MSN) and hollow silica nanoparticles (HSN) as therapeutic carriers for enzyme therapy. In our previous study, we have developed mesoporous silica nanoparticles (MSN) as enzyme delivery approach to successfully deliver superoxide dismutase (SOD) and glutathione peroxidase (GPx) into cells. The results demonstrated these denatured antioxidant enzymes conjugated on the MSN surface could be delivered and refolded with specific enzyme activity to protect cells attacked by ROS. The approach not only overcomes the challenges of protein delivery, including poor stability, membrane impermeability, endosome trapping/digestion and immune response, but provides the following advantages: (1) one-step protein conjugation and purification, (2) easy mass production and (3) multiple enzymes delivery to regulate cascade reactions. In the first part of this study, we aim to design an ideal MSN for use in vivo, achieving the characteristics of biocompatible, stability, and free of organ accumulation after administration. Hence, PEGylated MSN with polyethyleneimine (PEI) to increase cell uptake was synthesized, followed by the TAT-SOD conjugation to form RMSN-Ni-TAT-SOD. We compared the difference between the native and denatured form of RMSN-Ni-TAT-SOD after cell delivery, focusing on the mechanism study in details. From our results, we proposed that denatured form of TAT-SOD had less steric hindrance than native form when conjugated onto MSN, promoting efficiently delivery and result in enhanced SOD activity. In the second part, we report a novel approach to generate L-asparaginase (ASNase) encapsulated HSN by introducing silane strategy for the treatment of acute lymphoblastic leukemia (ALL). We investigated the shell of HSN was able to help internal ASNase against trypsin digestion and stabilize enzyme activity that would efficiently improve the problem of short half-life in vivo compared to free ASNase used in clinical now. In addition, the advantages of the approach retained good enzymatic activity which played a critical role in inducing cell apoptosis, a mainly therapeutic mechanism to ALL. To our best knowledge, this is the first work reporting the HSN encapsulated ASNase with good enzyme activity could be applied in treating ALL. Taken together, using silica nanoparticles to deliver protein is a promising approach. We expect this study would push the nano based protein therapy into preclinical, as well as attempt to address the current developmental and therapeutic challenges. |
URI: | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/77885 |
DOI: | 10.6342/NTU201703369 |
全文授權: | 有償授權 |
顯示於系所單位: | 化學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-R04223201-1.pdf 目前未授權公開取用 | 4.94 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。